Exact Sciences has launched Cologuard Plus, a next-generation, noninvasive colorectal cancer screening text, the company announced today.

According to a release, the Cologuard Plus test detects 95% of colorectal cancers at 94% specificity in the U.S. screening population compared to 92% and 87%, respectively, for the original Cologuard.

“Cologuard Plus builds on the proven performance of Cologuard,” Exact Sciences Executive Vice President and General Manager, Screening Jake Orville said in a statement. “Cologuard Plus delivers key enhancements to help improve patient care and streamline health care delivery, bringing us closer to eradicating this highly preventable and treatable disease.”

Key advancements of the Cologuard Plus test include fewer false positives and greater confidence in negative results.

The test is FDA-approved for average-risk individuals aged 45 and older and is covered by Medicare.